Company: KAVL
Filing Date: 2025-02-10
Form Type: 10-K
Source: 0001731122-25-000185
Chunk: 174

Company: Kaival Brands Innovations Group, Inc.
Filing Date: 2025-02-10
Form: 10-K
Item: Item 1A
Chunk 174
---
 equity securities in any future
offering or otherwise incur indebtedness will depend on market conditions and other factors beyond our control, we cannot predict or estimate
the amount, timing, or nature of our future offerings or financings, any of which could reduce the market price of our Common Stock and
dilute its value.

We may issue additional classes or series of
preferred stock whose terms could adversely affect the voting power or value of our commons stock. 

Our Certificate of Incorporation authorizes us to
issue, without the approval of our stockholders, one or more classes or series of preferred stock having such designations, preferences,
limitations, and relative rights, including preferences over our Common Stock respecting dividends and distributions, as our Board may
determine. The terms of one or more additional classes or series of preferred stock could adversely impact the voting power or value of
our Common Stock. For example, we might grant holders of preferred stock the right to elect some number of our directors in all events
or on the happening of specified events or the right to veto specified transactions. Similarly, the repurchase or redemption rights or
dividend or liquidation preferences we might assign to holders of preferred stock could affect the residual value of our Common Stock.

The market price for our Common Stock is volatile
and has and will fluctuate. 

The market price for shares of our Common Stock may
be volatile and subject to wide fluctuations in response to numerous factors, many of which are beyond our control, including the following:
(i) action by the FDA with respect to Bidi’s PMTAs or regulatory action by FDA generally against Bidi, our company or our industry,
(ii) actual or anticipated fluctuations in our quarterly financial results; (iii) recommendations by securities research analysts; (iv)
changes in the economic performance or market valuations of other issuers that investors deem comparable to ours; (v) addition or departure
of our executive officers or members of our Board and other key personnel; (vi) release or expiration of lock-up or other transfer restrictions
on outstanding shares of Common Stock; (vii) sales or perceived sales of additional shares of our Common Stock; (viii) the liquidity of
our Common Stock or lack thereof; (ix) significant acquisitions or business combinations, strategic partnerships, joint ventures, or capital
commitments by or involving us or our competitors; and (x) news reports relating to trends, concerns, technological or competitive developments,
regulatory changes, and other related issues in our industry or